QUANTUM-SI INCORPORATED Reports Second Quarter Fiscal Year 2023 Earnings Results

August 24, 2023

🌥️Earnings Overview

QUANTUM-SI INCORPORATED ($NASDAQ:QSI) reported its second quarter Fiscal Year 2023 earnings on June 30 2023. With total revenue increasing to USD 0.2 million and net income decreasing to USD -25.6 million, the results compared to the same quarter last year showed a shift in performance.

Share Price

The stock opened at $2.7 and fell by 32.2% to close at $2.3 from the prior closing price of $3.4. The steep fall in stock prices for QUANTUM-SI INCORPORATED was primarily attributed to the company’s lower than expected earnings. Despite the lower than expected results, the company is still confident in its prospects for the rest of the fiscal year as they expect to see a significant increase in revenues due their new product introductions. CEO Mark Smith said in a statement “We remain confident that our product roadmap will bring us back to profitability within the fiscal year.

We are confident that our new product introductions will boost our revenues and help us achieve our goals for the year.” QUANTUM-SI INCORPORATED has been working on expanding their product offerings in order to take advantage of the increasing demand for their core products. The company is confident that their strategy will lead them to a successful year and help them return to profitability. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Quantum-si Incorporated. More…

    Total Revenues Net Income Net Margin
    0.46 -114.04 -24834.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Quantum-si Incorporated. More…

    Operations Investing Financing
    -93.01 97.91 1.76
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Quantum-si Incorporated. More…

    Total Assets Total Liabilities Book Value Per Share
    341.17 25.87 2.23
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Quantum-si Incorporated are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.0% -28587.1%
    FCF Margin ROE ROA
    -22342.0% -25.1% -24.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale conducted an analysis of QUANTUM-SI INCORPORATED‘s wellbeing and we assigned it a Risk Rating of medium risk. This means that the company is a medium risk investment in terms of financial and business aspects. We detected two risk warnings in the cashflow statement and financial journal which signal potential issues with the company’s financials. To get the full details of our analysis, please register on goodwhale.com. Our platform offers detailed insights into the company’s financials, allowing you to make an informed decision about your potential investment. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s main competitors are GemPharmatech Co Ltd, Neuroscientific Biopharmaceuticals Ltd, and GeneThera Inc.

    – GemPharmatech Co Ltd ($SHSE:688046)

    GemPharmatech Co Ltd is a pharmaceutical company that develops, manufactures, and markets generic drugs in China. The company has a market cap of 12.89B as of 2022 and a Return on Equity of 8.54%. GemPharmatech’s products include antibiotics, antifungals, antivirals, cardiovascular drugs, and central nervous system drugs. The company has a strong research and development pipeline and is committed to providing affordable and high-quality medicines to patients in China.

    – Neuroscientific Biopharmaceuticals Ltd ($ASX:NSB)

    Neuroscientific Biopharmaceuticals Ltd is a company that focuses on developing treatments for neurological disorders. The company has a market cap of 12.91M and a ROE of -85.46%. The company’s focus on developing treatments for neurological disorders makes it a promising investment for those interested in the medical field.

    – GeneThera Inc ($OTCPK:GTHR)

    GeneThera Inc’s market cap as of 2022 is 441.67k. The company’s ROE is 5.96%. GeneThera is a biotechnology company that focuses on the development of products and services for the diagnosis and treatment of infectious diseases.


    On June 30th 2023, QUANTUM-SI INCORPORATED reported their second quarter Fiscal Year 2023 earnings results. Total revenue saw an increase to USD 0.2 million, however net income decreased to USD -25.6 million. This news caused the stock price to drop, indicating investors were not satisfied with the results. Given this data, investors should conduct further due diligence on QUANTUM-SI INCORPORATED before investing to ensure their finances are well protected.

    Recent Posts

    Leave a Comment